Pfizer’s Litfulo approved in Europe to treat severe alopecia areata
Litfulo works by irreversibly and selectively inhibiting JAK3 and the TEC family of kinases by blocking γ-common cytokine…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
20 Sep 23
Litfulo works by irreversibly and selectively inhibiting JAK3 and the TEC family of kinases by blocking γ-common cytokine…
20 Sep 23
The primary aim of these collaborations is to advance Merck's research endeavours and generate a range of innovative…
20 Sep 23
Under the agreement, PeptiDream will leverage its PDPS technology to discover, optimise, and develop macrocyclic peptide candidates for…
20 Sep 23
Co-developed by Japan-based Otsuka and British Astex, Inaqovi has been cleared by EC as monotherapy in AML patients…
20 Sep 23
Tevimbra is a humanised IgG4 anti-PD-1 monoclonal antibody designed to lower binding to Fc-gamma (Fcγ) receptors on macrophages,…
20 Sep 23
GT Molecular, Inc., a company providing ultrasensitive PCR assays for wastewater-based epidemiology testing, pathogen detection, and cancer research…
20 Sep 23
Rhythm is evaluating setmelanotide in a global Phase 3 clinical trial in acquired hypothalamic obesity and expects to…
20 Sep 23
Acceptance based on results from the Phase 3 LITESPARK-005 trial, which showed a statistically significant and clinically meaningful…
20 Sep 23
Danaher Corporation (NYSE: DHR) ("Danaher"), a global science and technology innovator, today announced it will provide Cepheid's Xpert® MTB/RIF Ultra…
20 Sep 23
Deep Bio, a leader in artificial intelligence (AI)-powered cancer diagnostics, announced today that it has obtained marketing authorization…